Ubiquitin-conjugating enzyme E2 L3 (EC 2.3.2.23) (E2 ubiquitin-conjugating enzyme L3) (L-UBC) (UbcH7) (Ubiquitin carrier protein L3) (Ubiquitin-conjugating enzyme E2-F1) (Ubiquitin-protein ligase L3)
1_MAASR 6_ RLMKE 11_ LEEIR 16_ KCGMK 21_ NFRNI 26_ QVDEA 31_ NLLTW 36_ QGLIV 41_ PDNPP 46_ YDKGA 51_ FRIEI 56_ NFPAE 61_ YPFKP 66_ PKITF 71_ KTKIY 76_ HPNID 81_ EKGQV 86_ CLPVI 91_ SAENW 96_ KPATK 101_ TDQVI 106_ QSLIA 111_ LVNDP 116_ QPEHP 121_ LRADL 126_ AEEYS 131_ KDRKK 136_ FCKNA 141_ EEFTK 146_KYGEK
1: Ubiquitin-conjugating enzyme E2 that specifically acts with HECT-type and RBR family E3 ubiquitin-protein ligases. Does not function with most RING-containing E3 ubiquitin-protein ligases because it lacks intrinsic E3-independent reactivity with lysine; in contrast, it has activity with the RBR family E3 enzymes, such as PRKN, RNF31 and ARIH1, that function like RING-HECT hybrids. Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. Mediates ubiquitination by the CUL9-RBX1 complex (PubMed:38605244). In vitro catalyzes 'Lys-11'-linked polyubiquitination. Involved in the selective degradation of short-lived and abnormal proteins. Down-regulated during the S-phase it is involved in progression through the cell cycle. Regulates nuclear hormone receptors transcriptional activity. May play a role in myelopoiesis